mabpharm.cn
About company
Mabpharm is a biopharmaceutical company in China, specializing in the development and production of new drugs and biosimilars for the treatment of cancer and autoimmune diseases.They are committed to bringing high-quality and affordable innovative biopharmaceuticals to the market through their highly efficient R&D systems and low-cost pharmaceutical production capabilities, and to leverage their extensive R&D experience to develop a wide range of therapeutic products. Their Taizhou Pharmaceutical production base has two buildings, each covering 15,000 square meters, and is housed in their single antibody production facility. Currently, their drug candidate pipeline currently includes 9 monoclonal antibody drugs, 3 of which are core products in Phase III clinical trials: CMAB007 (Omazumab), CMAB009 (Cetuximab) and CMAB008 (Inflix Infliximab). In addition, their other two drug candidates, CMAB809 (trastuzumab) and CMAB819 (navumab), have been approved for clinical trials.
